Lexicon Pharmaceuticals (LXRX) Cost of Revenue (2017 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Cost of Revenue of $108000.0 for Q1 2026, up 260.0% year-over-year from $30000.0 in Q1 2025, and down 46.27% quarter-over-quarter from $201000.0 in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Cost of Revenue (2017 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Cost of Revenue for 8 consecutive years, with $108000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 260.0% year-over-year to $108000.0; the TTM figure through Mar 2026 stood at $352000.0 (down 42.76% YoY), while the FY2025 annual figure was $274000.0, down 55.52% from the prior year.
- Cost of Revenue declined to $108000.0 in Q1 2026 per LXRX's latest filing, from $201000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $348000.0 in Q4 2024 and bottomed at $7000.0 in Q3 2023.
- Historically, Cost of Revenue has averaged $90250.0 across 4 years, with a median of $51500.0 in 2023.
- Annual changes were most pronounced in 2024 — Cost of Revenue jumped 1975.0% — and 2025, when it slumped 85.92%.
- Lexicon Pharmaceuticals' Cost of Revenue stood at $70000.0 in 2023, then soared by 397.14% to $348000.0 in 2024, then slumped by 42.24% to $201000.0 in 2025, then slumped by 46.27% to $108000.0 in 2026.
- Business Quant data shows LXRX's Cost of Revenue at $108000.0 in Q1 2026, $201000.0 in Q4 2025, and $10000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | 39,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39,000.00 |
| Mar 31, 2026 | 108,000.00 |
| Dec 31, 2025 | 201,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 33,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 348,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Jun 30, 2024 | 166,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Sep 30, 2023 | 7,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Sep 30, 2020 | 633,000.00 |
| Jun 30, 2020 | 728,000.00 |
| Mar 31, 2020 | 568,000.00 |
| Dec 31, 2019 | 774,000.00 |
| Sep 30, 2019 | 577,000.00 |
| Jun 30, 2019 | 1.33 Mn |
| Mar 31, 2019 | 553,000.00 |